Observatory of the Lille Paediatric Allergy Unit

NCT ID: NCT06634992

Last Updated: 2024-10-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to set up a paediatric observatory within the allergology department of The saint Vincent Hospital, Lille. The study aims to:

• Collect exhaustive prospective data from patients eligible for oral immunotherapy.

This prospective observatory will enable statistical analyses to be carried out on common food allergens such as hazelnut, cashew nut, pistachio and others.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

During the consultation, the allergist will inform the legal representative and the child about the terms of the study, and will provide them with an information note specifying the objectives of the study and its terms, the involvement of the child and his or her rights.

Depending on the allergen involved, the oral immunotherapy session will be assigned to one of three study groups: 1) allergen to hazelnut, walnut, pistachio, cashew or peanut,2) allergen to cow's milk, wheat or egg, 3) allergen to unusual foods: sesame, celery, fenugreek, peas, lentils, etc.

For each patient, and for each visit during the treatment period the collection of anthropometric, sociodemographic and medical data relating to oral food challenge will be done

Oral immunotherapy will then be started in accordance with standard practice. During this first visit, the investigator will give the patient a diary in which to record information about any IgE-mediated side-effects of the oral immunotherapy. Subsequent visits will follow the patient's usual routine until the desensitisation threshold is reached or the patient decides to stop the oral immunotherapy protocol. Visits will be made every 6 months, with a window of two months around each date.During these monitoring visits, tthe collection of anthropometric, sociodemographic and medical data relating to oral food challenge will be continue.

During each visit, a new food challenge test may be performed at the investigator's discretion to assess a new reactogenic threshold. Following this test, the following data will be collected:

* the cumulative dose ingested (mg food and mg food protein)
* the grade of the reaction (from 0 to 5 according to the Astier et Coll classification)
* achievement of desensitisation

A patient begins oral immunotherapy following food challenge test in a day hospital. Thus, a patient consulting at different times for several allergies and eligible for several oral immunotherapies will be able to take part in the study for several allergens. The follow-up of the different oral immunotherapies started (maximum 2 simultaneously, but could go up to 5, 6... over time) will be distinct. The patient may therefore participate several times in the study: in different groups, or in the same group, for different allergens. All the above data are collected separately for each new oral immunotherapy (except for socio-demographic data and information on previous oral immunotherapies, which are collected only at the time of inclusion).

In very rare cases, a patient may undergo several oral immunotherapies for the same allergen, but only the first oral immunotherapy (from the time the observatory was set up) will be taken into account in this study. If oral immunotherapy for the same allergen has already been carried out before the observatory was set up, the second oral immunotherapy for this allergen will not be included in the study, as its results will be biased.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Child Allergy IgE-Mediated Allergic Process Food Allergy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Allergy to hazelnut, walnut, pistachio, cashew or peanut

Oral immunotherapy

Intervention Type OTHER

Clinical Follow up

Group 2

Allergy to cow's milk, wheat or egg

Oral immunotherapy

Intervention Type OTHER

Clinical Follow up

Group 3

Allergy to unusual foods: sesame, celery, fenugreek, peas, lentils or others

Oral immunotherapy

Intervention Type OTHER

Clinical Follow up

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral immunotherapy

Clinical Follow up

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patient under 15 years and 9 months,
* positive diagnosis of food allergy (positive food challenge test or "highly probable allergy", defined by a convincing history, a positive prick test and IgE \> 0.35 kUA/L),
* eligible for oral food challenge
* accepting the following allergens : hazelnut, walnut, pistachio, cashew, peanut, cow's milk, wheat, egg, sesame, celery, fenugreek, pea, lentils or others

Exclusion Criteria

* Opposition
* Already received oral challenge for the same allergen.
Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lille Catholic University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tomas MORALY

Role: PRINCIPAL_INVESTIGATOR

Groupement des Hopitaux de l'institut catholique de Lille

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Groupement de l'Institut Catholique de Lille - Hôpital Saint Vincent de Paul

Lille, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Domitille Tristram

Role: CONTACT

+ 33 3 20 22 57 37

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tomas MORALY

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RNIPH-2021-36

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Oral Immunotherapy in Young Children With Food Allergy
NCT05738798 ENROLLING_BY_INVITATION NA
Food Oral Immunotherapy for Peanut Allergy
NCT04222491 ENROLLING_BY_INVITATION PHASE2
Lupine Allergy in Children
NCT06918249 COMPLETED
Study of Tolerance to Oral Peanut
NCT01259804 COMPLETED PHASE1
Tolerance Following Peanut Oral Immunotherapy
NCT01750879 COMPLETED PHASE1/PHASE2